Patients and physician satisfaction of Degarelix in androgen deprivation therapy for advanced hormone-dependent prostate cancer in the Netherlands

Autor: Hossain Roshani, Erik P.M. Roos, Henk W. Elzevier, Cees van de Beek, Peter van Winkel, Rob C.M. Pelger

Publikováno v: Current Urology, Vol 15, Iss 4, Pp 204-208 (2021)

Abstract. Background:. To explore the effectiveness and safety of the gonadotropin-releasing hormone antagonist, Degarelix, for the treatment of advanced hormone-dependent prostate cancer (PCa) in a real-world setting. Methods:. In this noninterventi

Externí odkaz: https://doaj.org/article/c2d38842bf694c1a930deeb803d5073b

Een α‑adrenerge receptorantagonist als behandeling van blaasontledigingsklachten bij vrouwen: Feit of fictie?

Autor: Kevin L. J. Rademakers, Cees van de Beek, Marlous L. E. Vermeulen

Publikováno v: Tijdschrift voor Urologie. 8:36-41

De behandeling van blaasontledigingsklachten bij vrouwen bestaat momenteel uit bekkenbodemfysiotherapie en intermitterende zelfkatheterisatie. Dit artikel betreft de effectiviteit van een α1-adrenerge receptorantagonist bij deze vrouwen. Hiertoe heb

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1caa24647fd11b7e048273d386e81ac4
https://doi.org/10.1007/s13629-017-0195-y

The Effect of Age on the Efficacy of Maintenance Bacillus Calmette-Guerin Relative to Maintenance Epirubicin in Patients with Stage Ta T1 Urothelial Bladder Cancer: Results from EORTC Genito-Urinary Group Study 30911

Autor: Richard J. Sylvester, Jorg R. Oddens, George van Andel, J. Alfred Witjes, Cees van de Beek, Wim J. Kirkels, Theo M. de Reijke, Maurizio A. Brausi, Stephen Prescott, Willem Oosterlinck

Publikováno v: European Urology, 66, 4, pp. 694-701
European Urology, 66(4), 694-701. Elsevier
European Urology, 66, 694-701
European urology, 66(4), 694-701. Elsevier

Item does not contain fulltext BACKGROUND: Although maintenance bacillus Calmette-Guerin (BCG) is the recommended treatment in high-risk non-muscle-invasive bladder cancer (NMIBC), its efficacy in older patients is controversial. OBJECTIVE: To determ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a61242b9e032d4407f092f2f51c004ab
https://pure.eur.nl/en/publications/50f840ae-4574-47bf-8912-ab7e1587d140

Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guerin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

Autor: Cees van de Beek, Aldo V. Bono, Levent Türkeri, Paolo Gontero, George van Andel, Willem Oosterlinck, Sandrine Marreaud, Sandra Collette, Maurizio A. Brausi, Richard J. Sylvester, Jorg R. Oddens, Wolfgang Hoeltl

Publikováno v: European Urology, 63(3), 462-472. Elsevier
European urology, 63(3), 462-472. Elsevier

Background The optimal dose and duration of intravesical bacillus Calmette-Guerin (BCG) in the treatment of non–muscle-invasive bladder cancer (NMIBC) are controversial. Objective To determine if a one-third dose (1/3D) is not inferior to the full

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::602298eef40381f428c6c8aa0959d0eb
https://doi.org/10.1016/j.eururo.2012.10.039

Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)

Autor: Roland Van Velthoven, Cees van de Beek, Pierre Scalliet, Marc Colombel, Geertjan van Tienhoven, Bertrand Tombal, Hein Van Poppel, Karin Haustermans, Paul C.M.S. Verhagen, Antony Verbaeys, Thomas C. Gasser, Alphonsus C.M. van den Bergh, Cora N. Sternberg, Laurence Collette, Jean-François Bosset, Michel Bolla, Theo M. de Reijke, Luigi F. Da Pozzo, K. Vekemans

Publikováno v: Lancet (UK), 380(9858), 2018-2027. Elsevier Ltd.
Lancet, 380(9858), 2018-2027. Elsevier Limited
LANCET, 380(9858), 2018-2027. ELSEVIER SCIENCE INC
Lancet, 380(9858), 2018-2027. Elsevier Science

We report the long-term results of a trial of immediate postoperative irradiation versus a wait-and-see policy in patients with prostate cancer extending beyond the prostate, to confirm whether previously reported progression-free survival was sustai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2641be4b96df2e8ccfc85960e011df54
https://pubmed.ncbi.nlm.nih.gov/24679462